Impact of taxanes on androgen receptor signaling.

Abstract

The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.

• Authors: Shanshan Bai, Bryan Y Zhang, Yan Dong
• Journal: Asian journal of andrology (Asian J Androl) 2019 May-Jun Vol. 21 Issue 3 Pg. 249-252 ISSN: 1745-7262 [Electronic] China
• PMID: 29900882 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Antineoplastic Agents, Phytogenic
• Receptors, Androgen
• Taxoids

Topics

• Antineoplastic Agents, Phytogenic (therapeutic use)
• Humans
• Male
• Prostatic Neoplasms, Castration-Resistant (drug therapy)
• Receptors, Androgen (drug effects)
• Signal Transduction (drug effects)
• Taxoids (therapeutic use)